Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion …

Nov 15, 2017 · Purpose: Approximately 40% of all glioblastomas have amplified the EGFR gene, and about half of these tumors express the EGFRvIII variant. The prognostic role of EGFRvIII …

Nov 14, 2017 · Purpose: Approximately 40% of all glioblastomas have amplified the EGFR gene, and about half of these tumors express the EGFRvIII variant.

Oct 14, 2013 · We document coexpression of EGFR and EGFRvIII in human tumors, identify a cell-intrinsic role for coexpression in vitro and in vivo, and demonstrate that EGFR and …

While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here, …

The epidermal growth factor receptor variant type III (EGFRvIII) is the most common mutation of EGFR in glioblastoma multiforme (GBM) and is found in approximately 25% of all GBMs. …

Jul 4, 2016 · EGFRvIII is known to contain a free cysteine that is not present in untruncated EGFR, and we have shown that this cysteine is critical for the activation of EGFRvIII and for its …

Epidermal growth factor receptor (EGFR) and EGFRvIII analysis is of current interest in glioblastoma – the most common malignant primary CNS tumor, because of new EGFRvIII …

Jun 18, 2013 · Although several EGFR mutations have been described, the most common extracellular mutation is EGFRvIII (also known as de2-7EGFR and ΔEGFR). EGFRvIII is a …

Oct 14, 2013 · We document coexpression of EGFR and EGFRvIII in human tumors, identify a cell-intrinsic role for coexpression in vitro and in vivo, and demonstrate that EGFR and …